IPSEN – Buy-back programme – Art 5 of MAR – Week 41 – 2023
Aggregated presentation by day and by market
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 09/10/2023 | FR0010259150 | 3 | 120.50 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 09/10/2023 | FR0010259150 | 1,697 | 121.18 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 10/10/2023 | FR0010259150 | 232 | 121.80 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 10/10/2023 | FR0010259150 | 34 | 122.00 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 10/10/2023 | FR0010259150 | 1,288 | 121.67 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 11/10/2023 | FR0010259150 | 72 | 122.37 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 11/10/2023 | FR0010259150 | 1,528 | 122.15 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 12/10/2023 | FR0010259150 | 24 | 120.80 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 12/10/2023 | FR0010259150 | 1,676 | 121.29 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 13/10/2023 | FR0010259150 | 40 | 119.00 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 13/10/2023 | FR0010259150 | 1,660 | 119.99 | XPAR |
| * Two-digit rounding after the decimal | TOTAL | 8,254 | 121.24 | |||
Attachment
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Half-year statement of IPSEN liquidity agreement – 2024 06 30
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis